• Explore /
  • Poster
  • / Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate.

Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate.

Abstract Poster

Authors

null

Kiwamu Okita

Shimonoseki Kohsei Hospital, Yamaguchi, Japan

Kiwamu Okita , Hiromitsu Kumada , Kenji Ikeda , Masatoshi Kudo , Seiji Kawazoe , Yukio Osaki , Masafumi Ikeda , Toshiyuki Tamai , Takuya Suzuki

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00946153

Citation

J Clin Oncol 30, 2012 (suppl 4; abstr 320)

DOI

10.1200/jco.2012.30.4_suppl.320

Abstract #

320

Poster Bd #

E4

Abstract Disclosures

Similar Posters

First Author: Masafumi Ikeda

First Author: Richard S. Finn

First Author: Jiayu Duan

First Author: Takeshi Terashima